Apr 12, 2014 - 9Infectious Diseases Division, Legnano Hospital Trust, Legnano, Italy;. 10Infectious ...... Sax p.e., tierNey c., collier a.c., et al. (2011). Ab-.
New Microbiologica, 37, 439-448, 2014
Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo Study Nicola Gianotti1, Andrea Poli1, Massimo Galli2, Angelo Pan3, Giuliano Rizzardini4, Alessandro Soria5, Pierluigi Viale6, Antonio Di Biagio7, Tiziana Quirino8, Paolo Viganò9, Paolo Bonfanti10, Antonella d’Arminio Monforte11, Ida Fortino12, Adriano Lazzarin1,13 Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy; 2 Infectious Diseases Clinic, Luigi Sacco University Hospital, Milan, Italy; 3 Infectious Diseases Division, Cremona University Hospital, Italy; 4 Infectious Diseases Division, Luigi Sacco University Hospital, Milan, Italy; 5 Infectious Diseases Division, San Gerardo Hospital, Monza, Italy; 6 Infectious Diseases Unit, Sant’Orsola-Malpighi Hospital, Bologna, Italy; 7 Infectious Diseases Clinic, San Martino Hospital, Genoa, Italy; 8 Infectious Diseases Division, Busto Arsizio Hospital Trust, Busto Arsizio, Italy; 9 Infectious Diseases Division, Legnano Hospital Trust, Legnano, Italy; 10 Infectious Diseases Division, Lecco provincial Hospital, Lecco, Italy; 11 Infectious and Tropical Diseases Clinic, San Paolo University Hospital, Milano, Italy; 12 Executive governance, Lombardy Region Health Trust, Italy; 13 Vita-Salute San Raffaele University, Milan, Italy 1
SUMMARY This study compared the cost-efficacy ratios of lopinavir/ritonavir monotherapy (LPV/r-MT) and of standard of care in virologically suppressed HIV-infected patients. The results of the efficacy and safety analyses are presented. We conducted a multicentre, randomised, open-label trial of HIV-infected adults on stable treatment, with HIVRNA
